Female Health Co., Aspen Park finalize merger

The Female Health Co.'s (FHC) transformational merger with Aspen Park Pharmaceuticals (APP) has been finalized with both sides agreeing to modified terms.
By merging, the two companies will bring together FHC's FC2 Female Condom and APP's wide drug development portfolio the features products design to address segments in the industry.
“We are extremely pleased to consummate this opportunity for our company and our shareholders,” FHC co-founder O.B. Parrish said.  “Our shareholders have shown substantial support for the merger with APP and it is in that spirit that the boards of both companies approved and agreed to the modified terms of the transaction.  Importantly, the consideration paid for APP’s business consists solely of existing authorized and currently available shares of FHC common and preferred stock.
"This transaction delivers on our objective to add and diversify our product offering with potentially high revenue, high margin products, while also mitigating the risks associated with being a single product company. The new Board of Directors and management team can now begin in earnest the process of moving forward with our strategic growth plans."